NDAINTRAMUSCULARSUSPENSION, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYPREXA RELPREVV is an extended-release intramuscular suspension of olanzapine pamoate indicated for maintenance treatment of schizophrenia and bipolar I disorder in patients stabilized on oral olanzapine. It is an atypical antipsychotic that works by antagonizing dopamine and serotonin receptors in the brain. The long-acting formulation provides therapeutic coverage for 2–4 weeks per injection, improving medication adherence in patients with psychotic disorders.
$0.004BPart D
LOE ApproachingProduct is in late-stage lifecycle with modest Medicare utilization (~3,700 claims in 2023), signaling a mature, stable team focused on retention and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia
Started Apr 2006
524 enrolled
Schizophrenia
Career Relevance
Working on ZYPREXA RELPREVV offers exposure to mature product management, market access strategy, and managed-care negotiation in a stable but declining revenue environment. Career growth typically involves transitioning to earlier-stage assets or expanding into adjacent therapeutic areas, as the LOE trajectory limits upside potential.
Brand Manager
Worked on ZYPREXA RELPREVV at Cheplapharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.